Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.52 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.41 |
| ▸ | TK2 | O00142 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8588339 | 1.00 | PYGM (0.56) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL1699647 | 0.92 | PYGM (0.56) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL2614693 | 0.92 | PYGM (0.56) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL12240330 | 0.92 | PYGM (0.56) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL15336921 | 0.89 | PYGM (0.61) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL10163761 | 0.89 | PYGM (0.61) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL13184452 | 0.88 | PYGM (0.56) | PYGMP2RY6DNPH1TK2 | |
| SCHEMBL20072701 | 0.80 | TK2 (0.47) | PYGMTK2 | |
| SCHEMBL24452332 | 0.80 | PYGM (0.56) | PYGMP2RY6P2RY14TK1TK2 | |
| SCHEMBL15367277 | 0.79 | PYGM (0.72) | PYGMP2RY6P2RY14TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130046006-A1 | INHIBITORS OF FAM3B GENE, INHIBITOR COMPOSITIONS, INHIBITING METHODS AND APPLICATIONS OF INHIBITORS IN PREPARING PHARMACEUTICALS | Suzhou Ribo Life Science Co., Ltd. (CN) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130046006-A1 | INHIBITORS OF FAM3B GENE, INHIBITOR COMPOSITIONS, INHIBITING METHODS AND APPLICATIONS OF INHIBITORS IN PREPARING PHARMACEUTICALS | FAM222B, FAM162A, FAM20C | PYGM 2562/4885P2RY6 4840/4885P2RY14 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.